TVTX
Travere Therapeutics, Inc.
Nasdaq: TVTX · San Diego, CA · Healthcare
$50.08-2.35 (-4.48%)Closed
Market Cap$4.72B
Cash$117.7Mmost recent
Runway9 mo$40.4M Q burn
P/E (TTM)—EPS $-0.29
52-Wk Range$26.79 – $67.52
Avg Volume2.0M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$50.08+176.8%
Pipeline
Drug candidates sponsored by Travere Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Sparsentan | Proteinuria+7 more | Recruiting | 2027-03 | 5 | |
| Phase 3 | Fosmetpantotenate | Pantothenate Kinase-Associated Neurodegeneration | Terminated | 2019-12-30past | 1 | |
| Phase 3 | Pegtibatinase | Homocystinuria | Recruiting | 2027-07 | 3 | |
| Phase 2 | RE-021 (Sparsentan) | Focal Segmental Glomerulosclerosis | Completed | 2016-06past | 1 | |
| Phase 1 | RE-021, sparsentan | Healthy Subjects | Completed | 2020-11-12past | 1 | |
| N/A | Unnamed | Cerebrotendinous Xanthomatosis (CTX) | Completed | 2021-02-19past | 1 | |
| N/A | Unnamed | Focal Segmental Glomerulosclerosis+1 more | Completed | 2023-10-31past | 1 | |
| N/A | Unnamed | Homocystinuria Due to CBS Deficiency | Completed | 2026-07-31past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for TVTX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.